Buy Clomipramine (Anafranil) Cas 303-49-1

Buy Clomipramine (Anafranil) Cas 303-49-1

Buy Clomipramine (Anafranil) Cas 303-49-1

Clomipramine, sold under the brand name Anafranil among others, is a tricyclic antidepressant (TCA).^[7] It is used in the treatment of various conditions, most notably obsessive–compulsive disorder but also many other disorders, including hyperacusis, panic disorder, major depressive disorder, trichotillomania,^[8] body dysmorphic disorder^[9][10][11] and chronic pain.^[7] It has also been notably used to treat premature ejaculation^[7] and the cataplexy associated with narcolepsy.^[12][13]

It may also address certain fundamental features surrounding narcolepsy besides cataplexy (especially hypnagogic and hypnopompic hallucinations).^[14] The evidence behind this, however, is less robust. As with other antidepressants (notably including selective serotonin reuptake inhibitors), it may paradoxically increase the risk of suicide in those under the age of 25, at least in the first few weeks of treatment.^[7]

It is typically taken by mouth, although intravenous preparations are sometimes used.^[15][16]

Common side effects include dry mouth, constipation, loss of appetite, sleepiness, weight gain, sexual dysfunction, and trouble urinating.^[7] Serious side effects include an increased risk of suicidal behavior in those under the age of 25, seizures, mania, and liver problems.^[7] If stopped suddenly, a withdrawal syndrome may occur with headaches, sweating, and dizziness.^[7] It is unclear if it is safe for use in pregnancy.^[7] Its mechanism of action is not entirely clear but is believed to involve increased levels of serotonin and norepinephrine.^[7]

Clomipramine was discovered in 1964 by the Swiss drug manufacturer Ciba-Geigy.^[17] It is on the World Health Organization’s List of Essential Medicines.^[18] It is available as a generic medication.^[7]

Clomipramine has a number of uses in medicine, including in the treatment of:

• Obsessive–compulsive disorder (OCD), which happens to be its only US FDATooltip Food and Drug Administration-labeled indication.^[19][20] Other regulatory agencies (such as the TGA of Australia and the MHRA of the UK) have also approved clomipramine for this indication.^{[21][22][23][24]}
• Major depressive disorder (MDD), a popular off-label use in the US. It is approved by the Australian TGA and the United Kingdom MHRA for this indication. In Japan it is also approved for depression.^{[21][22][23][24][25][26]} Some have suggested the possible superior efficacy of clomipramine compared to other antidepressants in the treatment of MDD,^{[27][28][29][30][31]} especially the more severe,^[32][33][34] although at the current time the evidence may be insufficient to more fully substantiate this claim.^[35]

As-with other tricyclic antidepressants, the antidepressant response specifically may be augmented, including in treatment-resistant cases, with triiodothyronine, at a dosage of 50 mcg.^{[36][37][38][39]} In the case of clomipramine specifically, this may also be the case with obsessive-compulsive disorder.

Buy Clomipramine (Anafranil) Cas 303-49-1

Buy Clomipramine (Anafranil) Cas 303-49-1

Buy Clomipramine (Anafranil) Cas 303-49-1

Buy Clomipramine (Anafranil) Cas 303-49-1

Buy Clomipramine (Anafranil) Cas 303-49-1

Buy Clomipramine (Anafranil) Cas 303-49-1

Buy Clomipramine (Anafranil) Cas 303-49-1

Buy Clomipramine (Anafranil) Cas 303-49-1

Clomipramine API — Overview

Clomipramine (CAS: 303-49-1, also known as clomipramina, chlorimipramine, Anafranil active ingredient, 3-chloroimipramine, and clomipramine free base) is a neurological API used in formulation, analytical-development, and research programs where local regulations permit. Suzhou Pharmaceutical Technology Co., Ltd. supplies Clomipramine API in controlled small-batch and bulk quantities from Suzhou, China, with export to Australia, New Zealand, Canada and South Korea. Export documentation: COA and MSDS standard for all orders.

Product Name	Clomipramine
Structural Formula
Alias	Clomipramina; Chlorimipramine; Anafranil active ingredient; 3-chloroimipramine; Clomipramine free base
CAS Number	303-49-1
Molecular Formula	C19H23ClN2
Molecular Weight	314.9 g/mol
Purity	Available by agreed HPLC specification
Appearance	White to off-white powder
Storage	Store sealed, protected from moisture and strong light

> Applications

Clomipramine is used by pharmaceutical and research organizations developing neurological formulations, reference methods, and impurity-control strategies. API supply is intended for qualified buyers who will confirm dosage form, salt-form strategy, impurity requirements, pharmacopoeial approach, and finished-dose registration obligations in their own markets.

Neurological formulation research

A 2005 American Journal of Psychiatry article reported a randomized, placebo-controlled trial evaluating exposure and ritual prevention, clomipramine, and their combination in adults with obsessive-compulsive disorder (Am J Psychiatry, doi:10.1176/appi.ajp.162.1.151, n=122). This supports the need for carefully controlled Clomipramine API quality in neurological formulation and analytical-development programs.

Analytical and impurity-control development

Buyers typically evaluate assay, related substances, residual solvents, water content, identity, salt conversion needs, and stability behavior before moving from sample quantities to pilot or commercial batches. We supply API only, not finished tablets, capsules, oral solutions, compounded preparations, or branded medicines.

> Sourcing & Supply

Suzhou Pharmaceutical Technology Co., Ltd. is an R&D-driven pharmaceutical company with in-house synthesis and analytical capability for Clomipramine API. Small batches (up to 10 kg) are produced directly by our technical team in Suzhou. For larger commercial quantities, production is scaled up at qualified manufacturing facilities, with export documentation provided according to the order scope.

• Small-batch orders (≤10 kg): prepared by our technical team in Suzhou. Lead time 10–14 business days from order confirmation.
• Commercial bulk (>10 kg): scaled up at qualified manufacturing facilities. Lead time 14–21 business days depending on batch size and documentation.

We export Clomipramine API to B2B buyers in Australia, New Zealand, Canada and South Korea.

> Quality & Export Documentation

All Clomipramine shipments are accompanied by a Certificate of Analysis (COA) confirming identity, appearance, assay, and related substances against batch specification. Purity is tested by HPLC against an authenticated reference standard. MSDS is provided for all orders, and Certificate of Origin (COO) is available for commercial bulk shipments.

> Packaging & Logistics

• 100 g, 500 g: double-layered aluminium foil bag, heat-sealed
• 1 kg: aluminium foil bag inside kraft paper box
• 5 kg, 10 kg: aluminium foil bag inside fibre drum
• >10 kg: packaging agreed according to commercial order requirements

Clomipramine API is shipped with moisture-protective packaging and batch labels matched to the COA. Shipping options include express courier for samples, air freight for kilogram orders, and sea freight for larger commercial shipments where timing allows.

> Pricing & Supply

Clomipramine pricing is provided on request. We do not publish list prices because the final quote depends on order quantity, purity requirement, salt-form needs, documentation needs, shipping destination, and current raw material costs.

• MOQ: 100 g for qualified buyers
• Sample policy: 10–50 g samples available for analytical confirmation
• Bulk discount tiers apply at 500 g, 1 kg, 5 kg, and 10 kg
• Payment: T/T (bank transfer). 100% in advance for standard orders. Terms for larger repeat orders by arrangement.

Clomipramine: Evidence vs. Comparators

---

SERT Affinity vs. Citalopram

Clomipramine demonstrates a uniquely high affinity for the serotonin transporter (SERT) among tricyclic antidepressants, a property that underpins its efficacy in OCD. In a direct head-to-head comparison using standardized in vitro binding assays, clomipramine’s Ki for SERT is 0.49 nM, which is approximately 10-fold more potent than the selective serotonin reuptake inhibitor (SSRI) citalopram (Ki = 4.82 nM) [1]. This high SERT affinity distinguishes clomipramine from other TCAs like desipramine, which is highly selective for NET, and imipramine, which has a more balanced but lower overall affinity profile.

Head-to-head

Ki 0.49 nM (Clomipramine) vs 4.82 nM (Citalopram)

Reported higher SERT affinity context

10-fold difference; supports SERT binding studies

Serotonin TransporterSERTBinding AffinityKiIn vitro pharmacology

︾

OCD Efficacy vs. SSRIs

A 2024 systematic review and meta-regression analysis of placebo-controlled trials for OCD, encompassing 20 studies and 3,890 participants, directly compared the efficacy of clomipramine to that of selective serotonin reuptake inhibitors (SSRIs). The analysis found that clomipramine was significantly more effective than SSRIs, even after statistically correcting for the risk of bias in the included studies [1]. The quantified difference in treatment effect, as measured by a meta-regression coefficient (β), was -0.58 (95% CI: -0.85 to -0.30, p < 0.001), demonstrating a robust and clinically meaningful superiority.

Head-to-head

Meta-regression β = -0.58 (95% CI -0.85 to -0.30, p

Reported endpoint response context

YBOCS-based; model-specific review

Head-to-head

47% vs 29% early improvement at week 1

Reported early improvement rate context

Placebo-controlled canine trial; N=268

Head-to-head

Kd 0.44 mg/kg for 50% NET occupancy

Reported in vivo NET occupancy context

PET imaging; parent and metabolite contribute

Class-level

30- to 90-fold variation in desmethylation

Metabolism context; source variability

CYP2D6 polymorphisms; TDM may be required

Specification review

Individual impurity ≤0.5%; Total ≤2.0%

Specification review context

USP monograph; supports method validation

Obsessive-Compulsive DisorderOCDMeta-analysisClinical EfficacyYBOCS

︾

Canine Separation Anxiety Efficacy

In a placebo-controlled, multi-site veterinary clinical trial for canine separation anxiety, the addition of clomipramine to a standardized behavioral modification program resulted in a significantly faster rate of clinical improvement. The study reported that after just one week of treatment, 47% of dogs receiving clomipramine (at 2-4 mg/kg/day) plus behavioral modification showed clinical improvement, compared to only 29% of dogs receiving behavioral modification alone [1]. This 62% relative increase in the early response rate demonstrates the compound’s value as an adjunctive therapy in veterinary behavioral medicine.

Clomipramine

Serotonin TransporterSERTBinding Affinity

Generic TCA substitution confounds receptor-binding profiles, undermining research reproducibility. Clomipramine (CAS 303-49-1) eliminates this variability with its uniquely high SERT affinity (Ki=0.14 nM), serving as the definitive positive control for OCD research (meta-regression β=-0.58 vs SSRIs, p<0.001).

Head-to-head

47% vs 29% early improvement at week 1

Reported early improvement rate context

Placebo-controlled canine trial; N=268

Veterinary Medicine

Clomipramine

CAS No.: 303-49-1

Cat. No.: VC0524030

Molecular Formula: C19H23ClN2

Molecular Weight: 314.9 g/mol

Purity: >98% (or refer to the Certificate of Analysis)

* For research use only. Not for human or veterinary use.

Inquiry

Product InfoOnline Inquiry

Specification

CAS No.	303-49-1
Molecular Formula	C19H23ClN2
Molecular Weight	314.9 g/mol
IUPAC Name	3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine
Standard InChI	InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3
Standard InChI Key	GDLIGKIOYRNHDA-UHFFFAOYSA-N
Impurities	N-[3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-t-yl)propyl]-N,N’,N’-trimethylpropane-1,3-diamine 3-(3-chloro-5H-dibenzo[b,f]azepin-5-yl]-N,N-dimethylpropan-1-amine 3-(3,7-dichloro-10,11-dihydro-5H-dibenzol[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine 3-chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine For more Impurities (Complete) data for Clomipramine (11 total), please visit the HSDB record page.
Canonical SMILES	CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl
Appearance	Solid powder
Boiling Point	160-170 °C at 3.00E-01 mm Hg 160-170 °C at 0.3 mm Hg
Melting Point	191.5-192 189.5 °C

Introduction

 

Pharmacological Profile of Clomipramine

Mechanism of Action

Clomipramine primarily inhibits the reuptake of serotonin (5-HT) and norepinephrine (NE) via binding to the sodium-dependent serotonin transporter (SLC6A4) and norepinephrine transporter (SLC6A2). Its active metabolite, desmethylclomipramine, contributes to noradrenergic effects, creating a dual mechanism that distinguishes it from selective serotonin reuptake inhibitors (SSRIs)   . At higher doses, clomipramine also exhibits antagonism at histamine H₁, muscarinic acetylcholine, and α₁-adrenergic receptors, leading to sedative, anticholinergic, and hypotensive side effects  .

Pharmacokinetics

• Absorption: Oral bioavailability is approximately 50%, with peak plasma concentrations occurring 2–6 hours post-dose  .
• Metabolism: Hepatic cytochrome P450 2D6 (CYP2D6) converts clomipramine to desmethylclomipramine, which has a half-life of 54–77 hours compared to the parent compound’s 19–37 hours  .
• Distribution: Protein binding exceeds 96%, with cerebrospinal fluid penetration confirmed in neuroimaging studies  .
• Elimination: Renal excretion accounts for 51–60% of clearance, with fecal elimination contributing 24–32%  .

Table 1: Comparative Pharmacokinetics of Clomipramine and SSRIs

Parameter	Clomipramine	Fluoxetine	Sertraline
Half-life (hours)	19–37	48–72	26–104
Protein Binding (%)	96–98	94–95	98
CYP450 Involvement	2D6, 3A4	2D6, 2C9	2B6, 2C9
Bioavailability (%)	~50	60–80	44

Clinical Applications

Obsessive-Compulsive Disorder (OCD)

Clomipramine remains the gold standard for OCD treatment, supported by meta-analyses showing a 30–40% reduction in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores   . In a 24-week open-label trial, intravenous clomipramine (50–225 mg/day) reduced Y-BOCS scores by 36.8% (p < 0.005), with sustained effects at follow-up . Comparative studies indicate superiority over amitriptyline and imipramine, though SSRIs are preferred first-line due to tolerability  .

Major Depressive Disorder (MDD)

While largely supplanted by SSRIs, clomipramine demonstrates efficacy in treatment-resistant depression. A double-blind study of 31 patients reported significant Hamilton Depression Rating Scale (HDRS) improvements (p < 0.001) within 10 days of intravenous administration  . Its noradrenergic activity may benefit patients with melancholic features  .

Panic Disorder

Clomipramine reduces panic attack frequency by 50–70% within 3 weeks, outperforming imipramine in early treatment phases (p < 0.05)  . Long-term studies show maintained efficacy for ≥12 months, with 68% remission rates in agoraphobia comorbidity  .

Off-Label Uses

• Premature Ejaculation: Daily 25–50 mg doses increase intravaginal ejaculatory latency time by 3–5-fold  .
• Chronic Pain: Neuropathic pain relief correlates with 5-HT receptor modulation in diabetic peripheral neuropathy  .
• Cataplexy: 75–150 mg/day reduces narcolepsy-associated cataplexy episodes by 60%  .

Event	Clomipramine (%)	Placebo (%)
Somnolence	54	14
Dry Mouth	85	20
Constipation	47	11
Weight Gain	18	4
Sexual Dysfunction	42	6

1. Clomipramine | 303-49-1 – ChemicalBook

   Aug 29, 2026 · Clomipramine (CAS 303-49-1) information, including chemical properties, structure, melting point, boiling point, …

   • Boiling point: bp0.3 160-170°
   • Melting point: 189.5°C

   • Density: 1.0568 (rough estimate)
   • refractive index: 1.5749 (estimate)

   CAS No.

   303-49-1

   Chemical Name:

   Clomipramine

   Synonyms

   CLOMIPRAMINE HCL;ANAFRANIL;CHLORIMIPRAMINE;CIM;g34586;G34596;5H-Dibe;G 34586;Hydiphen;CLOMIPRAMINE

   CBNumber:

   CB5173107

   Molecular Formula:

   C19H23ClN2

   Molecular Weight:

   314.85

   MDL Number:

   MFCD00242755

   MOL File:

   303-49-1.mol

   MSDS File:

   SDS

   Last updated:2026-08-29 11:56:07

   Product description	Number	Pack Size	Price
   Clomipramine ≥98%	CS-0012495	100mg	$222
   Clomipramine ≥98%	CS-0012495	250mg	$325
   3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine 98	AA002ZHR	10mg	$45
   3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine 98	AA002ZHR	25mg	$64
   3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine 98	AA002ZHR	50mg	$92
   More product size

   Request For Quotation

   Clomipramine Properties

   Melting point	189.5°C
   Boiling point	bp0.3 160-170°
   Density	1.0568 (rough estimate)
   refractive index	1.5749 (estimate)
   storage temp.	Sealed in dry,Room Temperature
   solubility	H2O: 25 mg/mL
   form	powder
   pka	pKa 9.38(H2O) (Uncertain)
   color	white to off-white
   CAS DataBase Reference	303-49-1(CAS DataBase Reference)
   EWG’s Food Scores	1
   FDA UNII	NUV44L116D
   ATC code	N06AA04
   NIST Chemistry Reference	Clomipramine(303-49-1)

    

   SAFETY

   Risk and Safety Statements

   Symbol(GHS)	GHS07,GHS08,GHS09
   Signal word	Danger
   Hazard statements	H410-H302-H370-H336
   Precautionary statements	P260-P264-P270-P307+P311-P321-P405-P501-P264-P270-P301+P312-P330-P501-P261-P271-P304+P340-P312-P403+P233-P405-P501-P273-P391-P501
   Hazard Codes	Xn
   Risk Statements	20/21/22
   Safety Statements	36
   WGK Germany	3
   RTECS	HN9055000
   Hazardous Substances Data	303-49-1(Hazardous Substances Data)
   REACH Registrations	Active

   Clomipramine price More Price(23)

   Manufacturer	Product number	Product description	CAS number	Packaging	Price	Updated	Buy
   ChemScene	CS-0012495	Clomipramine ≥98%	303-49-1	100mg	$222	2026-06-04	Buy
   ChemScene	CS-0012495	Clomipramine ≥98%	303-49-1	250mg	$325	2026-06-04	Buy
   aablocks	AA002ZHR	3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine 98	303-49-1	10mg	$45	2026-05-28	Buy
   aablocks	AA002ZHR	3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine 98	303-49-1	25mg	$64	2026-05-28	Buy
   aablocks	AA002ZHR	3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine 98	303-49-1	50mg	$92	2026-05-28	Buy

   Clomipramine Chemical Properties, Uses, Production

   Originator

   Anafranil,Ciba Geigy,Switz.,1968

   Uses

   Antidepressan.

   Definition

   ChEBI: A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressan s, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.

   Manufacturing Process

   22.9 parts of 3-chloroiminodibenzyl are dissolved in 300 parts by volume of xylene, and 4 parts of sodium amide, pulverized and suspended in toluene,are added thereto while stirring and maintaining the whole under a nitrogen atmosphere. The xylene solution immediately turns dark colored, but upon crystallization of the sodium salt therefrom it becomes again light-colored. The reaction mixture is stirred for about 2 hours at 80°C until the development of ammonia has terminated. A solution of γ-dimethylaminopropyl chloride in toluene, prepared by setting free a corresponding amount of the free base from 17.4 parts of its hydrochloride salt by addition of aqueous sodium hydroxide solution in about 10% excess, extraction with toluene and drying for 2 hours over anhydrous sodium sulfate is added to the xylene solution containing the sodium salt mentioned above and the whole is stirred under reflux for 15 hours. Precipitated sodium chloride is filtered off and the filtrate is concentrated. The residue is diluted with ether, and the hydrochloride of 3- chloro-5-(γ-dimethylaminopropyl)-iminodibenzyl is precipitated by introducing dry, gaseous hydrogen chloride. It is filtered off under suction and purified by repeated recrystallization from acetone; the pure substance melts at 191.5°C to 192°C.

   brand name

   Anafranil (Tyco).

   Therapeutic Function

   Antidepressant

   Mechanism of action

   Clomipramine is different from the other TCAs, exhibiting preferential selectivity for inhibiting the reuptake of 5-HT at the presynaptic neuronal membrane. Its antidepressant mechanism of action as an inhibitor of the 5-HT transporter is reduced in vivo, however, because of the formation of its active metabolite, N-desmethylclomipramine, which inhibits the reuptake of NE. As a result of its common structure with the other TCAs, clomipramine shares the pharmacological and adverse-effect profile of the other TCAs.
   The efficacy of clomipramine relative to the other TCAs in the treatment of obsessive-compulsive disorder may be related to its potency in blocking 5-HT reuptake at the presynaptic neuronal membrane, suggesting a dysregulation of 5-HT for the pathogenesis of obsessive-compulsive disorder. Clomipramine appears to decrease the turnover of 5-HT in the CNS, probably because of a decrease in the release and/or synthesis of 5-HT.
   Although in vitro studies suggest that clomipramine is approximately four times more potent than fluoxetine as a 5-HT reuptake inhibitor, in vivo studies suggest the opposite. This difference has been attributed to the relatively long elimination half-lives for fluoxetine and its principal serotonergic metabolite norfluoxetine. In addition, metabolism of clomipramine to its N-desmethyl secondary amine metabolite decreases the potency and selectivity of 5-HT -reuptake inhibition of clomipramine, but not fluoxetine.

   Pharmacokinetics

   Clomipramine appears to be well absorbed from the GItract following oral administration, with an oral bioavailability of approximately 50%, suggesting some first-pass metabolism. Food does not appear to substantially affect its bioavailability. Clomipramine and its active metabolite, N-desmethylclomipramine, exhibit nonlinear pharmacokinetics at 25 to 150 mg daily. At dosages exceeding 150 mg daily, their elimination half-lives may be considerably prolonged, allowing plasma concentrations of both to accumulate, which may increase the incidence of plasma concentration-dependent adverse effects, particularly seizures. Because of the relatively long elimination half-lives of clomipramine and N-desmethylclomipramine, their steady-state plasma concentrations generally are achieved within approximately 1 to 2 weeks. Plasma concentrations of N-desmethylclomipramine generally are greater than those for chlomipramine at steady-state conditions. Clomipramine crosses the placenta and is distributed into breast milk.
   Clomipramine is primarily metabolized by CYP2D6 N-dealkylation to its pharmacologically active metabolite, the 2- and 8-hydroxylated metabolites and their glucuronides, and clomipramine N-oxide. N-dealkylation also involves CYP3A4, CYP2C19, CYP2C9, and CYP1A2. Like all the other secondary amine TCAs, N-desmethylclomipramine is significantly more potent as an inhibitor of NE reuptake than clomipramine is. Although N-desmethylclomipramine is pharmacologically active, its efficacy in obsessive-compulsive disorder is not known. 8-Hydroxyclomipramine and 8-hydroxydesmethylclomipramine also are pharmacologically active, but their clinical importance remains unknown. The hydroxylation and N-demethylation of clomipramine highlight CYP2D6 polymorphism in healthy adults who were phenotyped as either extensive metabolizers or poor metabolizers of clomipramine. Interindividual variation in plasma concentrations may be caused by genetic differences in the metabolism of the drug. In addition, CYP1A2 ring hydroxylates clomipramine. Less than 1% of an oral dose of clomipramine was excreted unmetabolized into the urine, with 8-hydroxyclomipramine glucuronide as the principal metabolite found in the urine. The effects of renal clearance suggest that clomipramine and desmethylclomipramine should be decreased in patients with renal impairment.

   Clinical Use

   Clomipramine is considered to be the most powerful antidepressant ever made. This dihydrodibenzazepine TCA, with actions on both the NE and 5-HT transporters, was the last of the major TCAs to come to market. Initially, the U.S. FDA regarded it as another “me-too” drug, and accordingly, they did not license it. Subsequently, however, it was licensed for the treatment of obsessive-compulsive disorders. Clomipramine differs from imipramine only by the addition of a 3-chloro group.

   Side effects

   Male patients taking clomipramine should be informed of sexual dysfunction as a side effect associated with antidepressants having significant serotonergic activity. Sexual dysfunction in men appears as ejaculatory incompetence, ejaculatory retardation, decreased libido, or inability to obtain or maintain an erection. Sexual dysfunction is dose-related and may be treated by simply lowering the drug dose.

   Clomipramine synthesis

   

   

   Synthesis of Clomipramine from 5-Acetyl-3-chloro-10,11-dihydro-5H-dibenz[b,f]azepine

   Clomipramine Preparation Products And Raw materials

2. Clomipramine 303-49-1 – Pharmaceutical Raw Materials, Excipients …

   Clomipramine, sold under the brand name Anafranil among others, is a tricyclic antidepressant (TCA).

3. Clomipramine | 303-49-1 – MilliporeSigma

   Clomipramine; CAS Number: 303-49-1; Synonyms: 3- (3-chloro-10,11-dihydro-5H-dibenzo [b,f]azepin-5-yl)-N,N-dimethyl-1 …

4. Clomipramine | CAS No- 303-49-1 | Simson Pharma Limited

   Buy Clomipramine CAS No- 303-49-1, a high quality product from Simson Pharma Limited, a Leading Manufacturer and Exporter of …

   Clomipramine (303-49-1) for sale – vulcanchem.com

   VulcanChem offers qualified products for Clomipramine (CAS No. 303-49-1), please inquire us for more detail.

5. Clomipramine (CAS 303-49-1) | SERT/NET Dual Inhibitor | BenchChem

   Buy Clomipramine (CAS 303-49-1) from BenchChem. High-affinity SERT/NET dual inhibitor (Ki=0.14 nM SERT) for OCD & anxiety …

6. Clomipramine | 303-49-1 – MilliporeSigma

   Clomipramine; CAS Number: 303-49-1; Synonyms: 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1 …

7. 303-49-1 Clomipramine – Reference Standard – SynThink

   Clomipramine is used in Clomipramine impurity profiling as per limits and threshold values specified by respective drug legislations, …

8. Clomipramine 303-49-1 | MedChemExpress

   MedChemExpress provides Clomipramine CAS 303-49-1, related Reference Standards, Isotope-Labeled or GMP Grade …

9. Clomipramine Antidepressant CAS 303-49-1 | FMYYKJ Supply

   Suzhou Pharmaceutical Technology Co., Ltd. (China) supplies Clomipramine API CAS 303-49-1 for pharmaceutical B2B …